Security
Allogene Therapeutics, Inc. Common Stock · ALLO
ALLONASDAQCommon stockCurrentCIK 1737287Updated Oct 4, 2026
ALLO price & chart
Loading TradingView…
NASDAQ:ALLO on TradingView ↗About the company
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
In the news
Allogene Therapeutics Announces Participation in September Investor Conference ↗
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
4 filing
EFFECT filing
S-3 filing
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 415,905,000Source | 548,710,000Source | 750,128,000Source | 821,579,000Source |
| Property, Plant and Equipment, NetUSD | 72,839,000Source | 86,056,000Source | 109,849,000Source | 112,839,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 51,688,000Source | 75,218,000Source | 109,931,000Source | 61,904,000Source |
| Assets, CurrentUSD | 257,749,000Source | 303,386,000Source | 481,465,000Source | 528,824,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,539,000Source | 10,910,000Source | 10,241,000Source | 11,504,000Source |
| Operating Lease, Right-of-Use AssetUSD | 39,888,000Source | 45,205,000Source | 81,964,000Source | 83,592,000Source |
| Other Assets, NoncurrentUSD | 3,615,000Source | 2,325,000Source | 9,389,000Source | 9,564,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 123,363,000Source | 126,531,000Source | 158,118,000Source | 154,697,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 229,000Source | 212,000Source | 146,000Source | 144,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,010,709,000Source | -1,819,823,000Source | -1,334,936,000Source | -1,234,968,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 269,000Source | -89,000Source | -5,934,000Source | -9,926,000Source |
| Stockholders' Equity Attributable to ParentUSD | 292,542,000Source | 422,179,000Source | 592,010,000Source | 666,882,000Source |
| Additional Paid in Capital, Common StockUSD | 2,302,753,000Source | 2,241,879,000Source | 1,932,734,000Source | 1,911,632,000Source |
| Liabilities and EquityUSD | 415,905,000Source | 548,710,000Source | 750,128,000Source | 821,579,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 32,514,000Source | 35,523,000Source | 59,398,000Source | 53,728,000Source |
| Operating Lease, Liability, CurrentUSD | 8,208,000Source | 7,509,000Source | — | 6,002,000Source |
| Accounts Payable, CurrentUSD | 4,270,000Source | 5,394,000Source | 14,688,000Source | 13,890,000Source |
| Operating Lease, Liability, NoncurrentUSD | 75,045,000Source | 83,247,000Source | 93,514,000Source | 95,122,000Source |
| Other Liabilities, NoncurrentUSD | 15,804,000Source | 7,761,000Source | 5,205,000Source | 5,847,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 258,300,000Source | 373,100,000Source | — | 576,500,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -190,886,000Source | -257,590,000Source | -327,265,000Source | -340,414,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 12,359,000Source | 13,639,000Source | 14,200,000Source | 14,300,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 37,642,000Source | 51,743,000Source | 65,951,000Source | 83,600,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -1,231,000Source | -503,000Source | -7,502,000Source | 4,868,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 443,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -149,246,000Source | -200,300,000Source | -237,733,000Source | -220,519,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 95,559,000Source | 75,688,000Source | 163,289,000Source | 106,159,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 386,000Source | 694,000Source | 1,516,000Source | 5,191,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 30,157,000Source | 116,675,000Source | 95,695,000Source | 2,950,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -23,530,000Source | -7,937,000Source | 21,251,000Source | -111,410,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 61,980,000Source | 85,510,000Source | 93,447,000Source | 72,196,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 37,641,000Source | 51,743,000Source | 66,000,000Source | 83,600,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | 0Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 258,300,000Source | 373,100,000Source | 448,700,000Source | 576,500,000Source |
| DepreciationUSD | — | — | 14,199,000Source | 14,295,000Source |
| Equity Method Investment, Other than Temporary ImpairmentUSD | 0Source | 1,957,000Source | 7,000,000Source | — |
| General and Administrative ExpenseUSD | 56,781,000Source | 65,205,000Source | 71,673,000Source | 79,305,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | 0Source | -1,688,000Source | — | — |
| Income Tax Expense (Benefit)USD | 0Source | 443,000Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 1,075,000Source | 181,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -190,886,000Source | -257,590,000Source | -327,265,000Source | -340,414,000Source |
| Nonoperating Income (Expense)USD | 18,429,000Source | 16,052,000Source | 472,000Source | -4,878,000Source |
| Operating ExpensesUSD | 209,315,000Source | 273,221,000Source | 327,832,000Source | 335,692,000Source |
| Operating Lease, ExpenseUSD | 4,355,000Source | 5,264,000Source | 642,000Source | 2,433,000Source |
| Operating Lease, Lease IncomeUSD | 2,600,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | 215,000Source | -3,920,000Source | -17,835,000Source | -9,444,000Source |
| Payments to Acquire InvestmentsUSD | 138,257,000Source | 361,475,000Source | 438,629,000Source | 248,109,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | 91,112,000Source | 0Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 234,202,000Source | 432,459,000Source | 597,811,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 0Source | 22,000Source | 95,000Source | 156,000Source |
| Operating Income (Loss)USD | -209,315,000Source | -273,199,000Source | -327,737,000Source | -335,536,000Source |
| Other Nonoperating Income (Expense)USD | 215,000Source | -3,920,000Source | -17,835,000Source | -9,444,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -190,886,000Source | -257,147,000Source | — | — |
| Income Tax Expense (Benefit)USD | 0Source | 443,000Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -190,886,000Source | -257,590,000Source | -327,265,000Source | -340,414,000Source |
| Earnings Per Share, BasicUSD per share | -0.87Source | -1.32Source | -2.09Source | -2.38Source |
| Earnings Per Share, DilutedUSD per share | -0.87Source | -1.32Source | -2.09Source | -2.38Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 220,622,669Source | 194,811,756Source | 156,931,778Source | 143,147,165Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 220,622,669Source | 194,811,756Source | 156,931,778Source | 143,147,165Source |
| Interest Expense (non-operating)USD | 1,075,000Source | 181,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | — | — | 0Source |
| Common Stock, Dividends, Per Share, DeclaredUSD per share | 0Source | 0Source | 0Source | 0Source |
| Current Income Tax Expense (Benefit)USD | 0Source | 0Source | — | — |
| General and Administrative ExpenseUSD | 56,781,000Source | 65,205,000Source | 71,673,000Source | 79,305,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -190,886,000Source | — | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | 0Source | -1,688,000Source | — | — |
| Interest and Other IncomeUSD | 19,289,000Source | 20,153,000Source | 18,307,000Source | 4,566,000Source |
| Nonoperating Income (Expense)USD | 18,429,000Source | 16,052,000Source | 472,000Source | -4,878,000Source |
| Operating ExpensesUSD | 209,315,000Source | 273,221,000Source | 327,832,000Source | 335,692,000Source |
| Operating Lease, ExpenseUSD | 4,355,000Source | 5,264,000Source | 642,000Source | 2,433,000Source |
| Operating Lease, Lease IncomeUSD | 2,600,000Source | — | — | — |
| Research and Development ExpenseUSD | 150,152,000Source | 192,299,000Source | 242,914,000Source | 256,387,000Source |
Offerings
Registration 333-298268
Filing attachments
d283634dex991.htm · 8-K · 2026-04-15
EX-99.1 4 d283634dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) - Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $175 million of shares of its common stock. All of the shares are being offered by Allogene. In addition, Allog…
Read attachment ↗d283634dex992.htm · 8-K · 2026-04-15
EX-99.2 5 d283634dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Allogene Therapeutics Announces Pricing of Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif., April 14, 2026 - Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the pricing of an underwritten public offering of 87,500,000 shares of its common stock at a price to the public of $2.00 per share. The gross proceeds from this offering are expected to be $175 million, before deducting underwriting discounts and commissi…
Read attachment ↗